Madison Vaccines, a life sciences firm developing therapies for prostate cancer, closes $8m series A.

Life sciences firm Madison Vaccines has raised $8m in series A to further develop therapies focused on prostate cancer.

The round was led by venture firm Venture Investors, and joined by Venture Management and the State of Wisconsin Investment Board. The Wisconsin Alumni Research Foundation (WARF) also joined the round, which also licensed the technologies to Madison – originally developed at the University of Wisconsin-Madison.

The funding will be used to support the clinical trials of Madison’s primary technology MVI-816…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?